Figure 5. The anti-tumor activity of triple therapy is CD4⁺ T cell dependent.

Kaplan Meier survival curves for untreated animals, triple therapy (no depletion), triple therapy with depleted CD4⁺ T cells and triple therapy with depleted CD8⁺ T cells (n = 5–7 mice/group). CD4⁺ T cell depletion abolishes the survival benefit of triple therapy (p<0.001). Depletion of CD8⁺ T cells did not interfere with the efficacy of triple therapy and resulted in long-term survival.